The first medication
approved by the FDA
to treat advanced
medullary thyroid
cancer (aMTC)

Support and Resources

Access and Reimbursement Support

The CAPRELSA Access Support program is provided through Biologics, Inc., a specialty pharmacy that supports your patients with a dedicated, personalized approach. The Biologics pharmacy team will be in touch with your patients throughout their treatment to explain insurance benefits, answer questions about CAPRELSA, and explore financial assistance options to cover the cost of treatment.

The CAPRELSA Access Support Team is here to help your patients access therapy:

  • Benefit verification and prior authorization support
  • Access to CAPRELSA copay program for commercially insured patients
  • CAPRELSA Patient Assistance Program for patients who are uninsured or have inadequate insurance coverage for CAPRELSA
  • CAPRELSA Interim Access Program
  • Information about other programs that may provide financial assistance for eligible applicants

Throughout the course of therapy, the Biologics pharmacy team will:

  • Provide 24/7 access to a clinical oncology pharmacist
  • Call your patients to make sure they have the tools they need to help them stay on treatment
  • Contact your patients to remind them of upcoming refills

To learn more, visit

CAPRELSA Access Support

pharmacy contact

For pharmacy-related inquiries, please call:


patient contact

For patient assistance inquiries, please call:



Fax your prescriptions for CAPRELSA to:


The CAPRELSA Welcome Kit

The CAPRELSA Welcome Kit has been created to help answer your patients’ questions about the treatment of their aMTC with CAPRELSA. When your patients start treatment with CAPRELSA, they will receive the CAPRELSA Welcome Kit from Biologics, which includes:

  • CAPRELSA Patient Brochure
  • Guide to Understanding CAPRELSA Side Effects
  • Support Magnet
  • CAPRELSA Medication Guide
  • CAPRELSA Prescribing Information

Important Safety Information, including Boxed WARNING, for CAPRELSA


  • CAPRELSA can prolong the QT interval. Torsades de pointes and sudden death have occurred in patients receiving CAPRELSA
  • Do not use CAPRELSA in patients with hypocalcemia, hypokalemia, hypomagnesemia, or long QT syndrome. Correct hypocalcemia, hypokalemia and/or hypomagnesemia prior to CAPRELSA administration
  • Monitor electrolytes periodically
  • Avoid drugs known to prolong the QT interval
  • Only prescribers and pharmacies certified with the restricted distribution program are able to prescribe and dispense CAPRELSA
  • Do not use in patients with congenital long QT syndrome
  • CAPRELSA can prolong the QT interval in a concentration-dependent manner. Torsades de pointes, ventricular tachycardia and sudden deaths have occurred in patients treated with CAPRELSA
  • Do not start CAPRELSA treatment in patients whose QTcF interval (corrected QT interval, Fridericia) is greater than 450 ms or who have a history of Torsades de pointes, bradyarrhythmias, or uncompensated heart failure. CAPRELSA has not been studied in patients with ventricular arrhythmias or recent myocardial infarction
  • Stop CAPRELSA in patients who develop a QTcF greater than 500 ms until QTcF returns to less than 450 ms. Dosing of CAPRELSA can then be resumed at a reduced dose
  • Because of the risk of QT prolongation, obtain an ECG and serum potassium, calcium, magnesium, and thyroid-stimulating hormone (TSH) at baseline, 2-4 weeks and 8-12 weeks after starting treatment with CAPRELSA, and every 3 months thereafter. Following any dose reduction or interruptions greater than 2 weeks, conduct QT assessments as described above
  • Severe skin reactions (including Stevens-Johnson syndrome and Toxic Epidermal Necrolysis), some leading to death, have occurred in patients treated with CAPRELSA. For severe skin reactions, refer patients for urgent medical advice. Systemic therapies e.g., steroids, may be appropriate in such cases and permanent discontinuation of CAPRELSA is recommended
  • Photosensitivity reactions can occur during CAPRELSA treatment and up to 4 months after treatment discontinuation
  • Interstitial lung disease (ILD) or pneumonitis, including fatalities, has occurred in patients treated with CAPRELSA. Interrupt CAPRELSA for acute or worsening pulmonary symptoms and discontinue CAPRELSA if ILD is confirmed
  • Ischemic cerebrovascular events, including fatalities, occurred in patients treated with CAPRELSA. The safety of resumption of CAPRELSA therapy after resolution of an ischemic cerebrovascular event has not been studied. Discontinue CAPRELSA in patients who experience a severe ischemic cerebrovascular event
  • Serious hemorrhagic events, including fatalities, occurred in patients treated with CAPRELSA. Do not administer CAPRELSA to patients with a recent history of hemoptysis of ≥1/2 teaspoon of red blood. Discontinue CAPRELSA in patients with severe hemorrhage
  • Heart failure, including fatalities, occurred in patients treated with CAPRELSA. Monitor for signs and symptoms of heart failure. Consider discontinuation of CAPRELSA in patients with heart failure. Heart failure may not be reversible upon stopping CAPRELSA
  • Diarrhea of Grade 3 or greater severity occurred in patients receiving CAPRELSA. If diarrhea occurs, carefully monitor serum electrolytes and ECGs to enable early detection of QT prolongation resulting from dehydration. Interrupt CAPRELSA for severe diarrhea and upon improvement resume CAPRELSA at a reduced dose
  • Increased dosing of thyroid replacement therapy was required in 49% of CAPRELSA-treated patients. Obtain TSH at baseline, at 2-4 weeks and 8-12 weeks after starting treatment with CAPRELSA, and every 3 months thereafter. If signs or symptoms of hypothyroidism occur, examine thyroid hormone levels and adjust thyroid replacement therapy accordingly
  • Hypertension, including hypertensive crisis, has occurred in patients treated with CAPRELSA. Monitor all patients for hypertension. Dose reduction or interruption for hypertension may be necessary. If hypertension cannot be controlled, do not resume CAPRELSA
  • Reversible posterior leukoencephalopathy syndrome (RPLS) has occurred in patients treated with CAPRELSA. Consider this syndrome in any patient presenting with seizures, headache, visual disturbances, confusion or altered mental function. In clinical studies, three of four patients who developed RPLS while taking CAPRELSA also had hypertension. Discontinue CAPRELSA treatment in patients with RPLS
  • Avoid administration of CAPRELSA with anti-arrhythmic drugs and other drugs that may prolong the QT interval
  • Vandetanib exposure is increased in patients with impaired renal function. Reduce the starting dose to 200 mg in patients with moderate to severe renal impairment and monitor the QT interval closely. There is no information available for patients with end-stage renal disease requiring dialysis
  • CAPRELSA is not recommended for patients with moderate and severe hepatic impairment, as safety and efficacy have not been established
  • CAPRELSA has the potential to adversely affect wound healing. Withhold for at least 1 month prior to elective surgery. Do not administer CAPRELSA for at least 2 weeks following major surgery and until adequate wound healing. The safety of resumption of treatment with CAPRELSA after resolution of wound healing complications has not been established
  • CAPRELSA can cause fetal harm when administered to a pregnant woman. Women of childbearing potential should avoid pregnancy and be advised that they must use effective contraception during CAPRELSA treatment and for at least 4 months following the last dose of CAPRELSA
  • The most commonly reported adverse drug reactions (>20%) seen with CAPRELSA and with a between arm difference of ≥5% are diarrhea/colitis (57%), rash (53%), acneiform dermatitis (35%), hypertension (33%), nausea (33%), headache (26%), upper respiratory tract infections (23%), decreased appetite (21%), and abdominal pain (21%)
  • CAPRELSA REMS Program: Because of the risks of QT prolongation, Torsades de pointes, and sudden death, CAPRELSA is available only through the CAPRELSA REMS Program. Only prescribers and pharmacies certified with the restricted distribution program are able to prescribe and dispense CAPRELSA. To learn about the specific REMS requirements and to enroll in the CAPRELSA REMS Program, call 1-800-817-2722 or visit

Indications and Usage

CAPRELSA is a kinase inhibitor indicated for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease.

Use CAPRELSA in patients with indolent, asymptomatic or slowly progressing disease only after careful consideration of the treatment related risks of CAPRELSA.

Please see full Prescribing Information for CAPRELSA, including Boxed WARNING.